Adia Nutrition Inc (PK) (ADIA) Share Price

If you dont have any time for the pumpers, why didnt you put them on ignore. Its literally everyone on this board.

I think the real investors are holding back until they see an independent (not a friend) CPA audit, minimum listing on the OTCQB exchange, revenue coming in verified by the independent CPA firm, no more pumping the stock, etc.

I put Natural Trader and Samson8 on ignore. I don't have any use for these type of unprofessional posters as well as pumpers. I invite real professionals for their comments.

clown stock pumping

going over .10 lol buy it then

Promoters leave this one and move over to INKW?

Quick someone slap 100 shares to make it look like people are buying this.........

Adia Med to Expand Treatment Offerings with Therapeutic Plasma Exchange (TPE) Across All Future Full Clinic Locations
Winter Park, Florida--(Newsfile Corp. - March 17, 2025) - Adia Nutrition (OTC Pink: ADIA), a leader in innovative healthcare solutions, is thrilled to announce that its subsidiary, Adia Med, will ensure that all future full clinic locations across the United States will offer Therapeutic Plasma Exchange (TPE), with its current location already offering this advanced treatment as of today. These full clinics, which will also perform Hematopoietic Stem Cell Transplantation (HSCT) for various conditions using state-of-the-art apheresis machines, will integrate TPE into their offerings, leveraging the same cutting-edge equipment. This forward-thinking expansion will unlock a wide range of applications, including potential benefits for Alzheimer's disease, reinforcing Adia Med's commitment to pioneering patient care.

Cannot view this image? Visit: https://images.newsfilecorp.com/files/10520/243472_1.jpg

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/243472_70824-9959585.jpeg

TPE, a procedure that utilizes an apheresis machine to remove and replace a patient's plasma, will target harmful substances—such as autoantibodies, immune complexes, and toxins—in the bloodstream, offering hope for numerous conditions, including neurodegenerative diseases like Alzheimer's. With all future Adia Med full clinics set to utilize apheresis technology for HSCT, they will seamlessly adopt TPE, maximizing the potential of this sophisticated equipment. The current Adia Med location, now offering TPE, marks the first step in this transformative vision.

"We are excited to announce that all our future full clinics will provide TPE, a treatment with immense potential to change lives, including for those affected by Alzheimer's," said Larry Powalisz, CEO of Adia Med. "Our current location is already delivering this therapy, and as we grow, every new full clinic equipped with top-tier apheresis machines will expand access to this innovative care. As one of just three clinic networks in the U.S. with this technology, we will continue to lead the charge in advanced medical solutions."

Studies have highlighted the promising benefits and versatility of TPE across various conditions, including Alzheimer's disease. A study published in Alzheimer's & Dementia explored the AMBAR trial, which showed that TPE combined with albumin replacement slowed cognitive and functional decline in patients with mild-to-moderate Alzheimer's, suggesting that removing amyloid-beta proteins and other toxic plasma components could play a key role in disease management. Notably, insurance has already covered TPE for Alzheimer's applications in some cases, reflecting growing recognition of its potential.

Additionally, research in Transfusion and Apheresis Science demonstrated TPE's ability to reduce mortality in moderate-to-critical COVID-19 patients, with a risk ratio of 0.41 (95% CI 0.24 to 0.69), underscoring its broader life-saving potential. The American Society for Apheresis (ASFA) also recognizes TPE as a first-line therapy for conditions like Guillain-Barré Syndrome, Myasthenia Gravis, and Thrombotic Thrombocytopenic Purpura (TTP), where it will swiftly remove disease-causing agents to improve outcomes. Future applications may extend to autoimmune disorders, other neurological conditions, and certain drug overdoses, showcasing TPE's extensive therapeutic reach.

The national average cost for TPE ranges from $4,000 to $6,000 per patient, depending on factors like facility fees, the number of sessions required, and regional pricing differences. With Florida's large retiree population—over 4.5 million residents aged 65 and older, many of whom face age-related conditions like Alzheimer's and autoimmune disorders—Adia Med sees a significant market for this treatment. This demographic, combined with the state's growing healthcare infrastructure, positions Florida as an ideal hub for expanding TPE access, addressing a critical need among retirees seeking advanced therapeutic options.

Patients and healthcare providers eager to explore TPE and other services at Adia Med's clinics can visit www.adiamed.com or contact 321-788-0850 for more information as these offerings roll out.

https://www.newsfilecorp.com/release/243472/Adia-Med-to-Expand-Treatment-Offerings-with-Therapeutic-Plasma-Exchange-TPE-Across-All-Future-Full-Clinic-Locations

$ADIA

Snake oil

very nice news , going over .10 today https://www.otcmarkets.com/stock/ADIA/news/Adia-Med-to-Expand-Treatment-Offerings-with-Therapeutic-Plasma-Exchange-TPE-Across-All-Future-Full-Clinic-Locations?id=470666

yea I think itll do it today doesnt take much to do it

General question here but why is Rebecca Miller the CFO of ADIA buying the Reg A of Steve Carnes other companies (INKW and GMZP) and then flipping the shares? Seems like a self enrichment scheme like they got convicted of by the SEC before.

Pump and dump

"We're committed to innovation, accessibility, and sustainable growth for our stakeholders."

The share retirement effort further solidifies corporate governance, amplifying investor confidence, as ADIA Nutrition strengthens its position as a leader in regenerative medicine innovation.

The OTCQB uplisting process, now in clear sight with the shell risk designation lifted

"This is just the start."

These February triumphs build on January's success, when the Adia Med Winter Park Clinic exceeded financial expectations in its first operational month, covering all opening expenses with surplus revenue

This Comany is Something Special!!! Watch!!!

This Comany is Something Special!!! Watch!!!

Adia will alway do what is in the best interest of the company and Adia's shareholders.

https://www.newsfilecorp.com/release/242492/ADIA-Nutrition-Inc.-Ignites-2025-with-February-Breakthroughs-Riding-Adia-Meds-Profitable-January-Triumph

New HIGH OF .095!

Pump and dump

Possibility!

Waiting for $1.00+

Hit .095 Today!

Nice volume came in this afternoon.

Would like to see this back over .10 next week!

$ADIA

dome decent buys coming in at 09 this afternoon

Accumulation

Some interesting buying coming now. All buys today, so far:

A whopping $117 of prop volume to keep the price at .09. I bet none of you pumpers even know the annual report came out this week. That or you dont want to mention it because it states theyll need money and will need to use the Reg A at .005

$ADIA churning green here. just a matter of time before this breaks out.

Plus the company is working with a PCAOB-registered accounting firm to complete a third-party audit—the first step in its plan to uplist to OTCQB and eventually Nasdaq Small Cap!

Here’s why this matters:

✅ OTCQB uplisting = More credibility & transparency 📊
✅ Increased liquidity = More trading volume, stronger price action 💰
✅ Bigger investor base = Institutional money on the horizon 💵
✅ Roadmap to Nasdaq Small Cap is in place 🚀

Way overbought and pumped. Looks like someone bought 100 shares at the close to paint the mark.

$ADIA is +1,320.00% on its 50 DMA!

ADIA Continues to Scale Up! >>

Adia Nutrition Hunts for Top Sales Talent to Power Adia Med and Adia Labs Expansion
https://www.newsfilecorp.com/release/243941/Adia-Nutrition-Hunts-for-Top-Sales-Talent-to-Power-Adia-Med-and-Adia-Labs-Expansion

PR'ng job postings? Why?

That's the kind of news I really wanted to see.

news https://www.otcmarkets.com/stock/ADIA/news/Adia-Nutrition-Hunts-for-Top-Sales-Talent-to-Power-Adia-Med-and-Adia-Labs-Expansion?id=470454

$ADIA Up On The Day! Great loading opps out here!

Adia has undergone a major transformation—shifting from nutritional supplements to stem cell research & regenerative medicine. The company recently launched its first clinic and is already planning expansions.

📊 Technical indicators suggest upside:
✔ Trading above all key SMAs (8, 20, 50, 200-day)
✔ MACD & accumulation trends pointing bullish
✔ RSI at 58.71—showing strength without overbought conditions
✔ Resistance at $0.09 tested multiple times, with upside potential to $0.12–$0.15

With growing institutional interest in stem cell therapy, will $ADIA retest its 52-week high of $0.1720? Keep it on your watchlist! 🚀 #Biotech #StemCell #ADIA

yep

Weird how no one here posted about the annual filing filed yesterday. Over $200k net loss and said they'll need to use the Reg A for funding. Why did no one even talk about it today? Oh because everyone posting here is paid to be here and push this on unsuspecting buyers. It doesn't work anymore.

Plans for nationwide expansion.

Yup, staying on track. Expansion happening

It's just a matter of time before $ADIA breaks out!

agreed

Great stream of news by the company, here's today's press release! >>

ADIA Nutrition Strengthens Team to Optimize Operations and Advance Regenerative Medicine Excellence
Winter Park, Florida--(Newsfile Corp. - March 11, 2025) - ADIA Nutrition Inc. (OTC Pink: ADIA), a leader in healthcare innovation and regenerative medicine, is proud to announce the expansion of its workforce with two strategic hires designed to enhance operations and elevate standards in stem cell therapy. These additions reflect ADIA Nutrition's dedication to scaling its Adia Med division with efficiency and innovation as it grows nationwide.

ADIA Nutrition has welcomed a skilled intake nurse to manage patient-facing responsibilities at the Adia Med Winter Park Clinic. At this location, she will handle traditional intake duties meanwhile assisting doctors with patient assessments, medical history reviews, and treatment plan coordination, ensuring a seamless experience for clients seeking regenerative therapies. Beyond Winter Park, she will work directly with doctors to create compliance standards and write best practices for stem cell treatments across all Adia Med locations, relieving them of some administrative workload. This support allows physicians to focus on developing the best procedures for patients and continuously improving the effectiveness of regenerative medicine, ensuring consistent quality and regulatory alignment as the company expands.

Additionally, ADIA Nutrition has promoted Larry Powalisz's intern of three years into a role as the CEO's aide. This trusted team member will take on many individual projects previously managed by Powalisz, including handling marketing efforts and social media strategy, significantly reducing the CEO's day-to-day responsibilities. This shift relieves Powalisz from dealing with specific project details, enabling him to concentrate on the bigger picture—maximizing the reach and success of ADIA Nutrition as it expands its influence in the healthcare sector.

"These hires are a massive boost for ADIA Nutrition," said Larry Powalisz, CEO of ADIA Nutrition. "Our new intake nurse will deliver top-tier care at Winter Park while partnering with our doctors to set compliance and stem cell standards, freeing them to innovate for our patients. Meanwhile, my aide taking on projects, marketing, and social media lets me focus on driving our broader vision and expanding our brand. Together, they're powering our growth and pushing regenerative medicine forward."

These hires come on the heels of ADIA Nutrition's recent successes, including the profitable launch of the Adia Med Winter Park Clinic and plans for nationwide expansion. The intake nurse's collaboration with doctors on compliance and standards will ensure scalable, high-quality care, while the CEO's aide enhances operational agility and visibility, solidifying ADIA Nutrition's leadership in delivering cutting-edge, accessible regenerative therapies.

For questions, inquiries, or further information, contact Larry Powalisz at ceo @101Dahlias-0850.

About ADIA Nutrition Inc.:
ADIA Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, it operates two key divisions: a supplement division offering premium, organic supplements, and a medical division establishing clinics specializing in leading-edge stem cell therapies, including Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these efforts, ADIA Nutrition empowers individuals to live their best lives by addressing nutritional needs and groundbreaking medical treatments.

Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.biolete.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition

https://finance.yahoo.com/news/adia-nutrition-strengthens-team-optimize-141500079.html

$ADIA

Nice update out. Additionally, ADIA Nutrition’s CEO, Larry Powalisz, has promoted his longtime intern to aide, offloading key projects, marketing, and social media. This change allows leadership to focus on strategic expansion while maintaining our mission-driven approach.